Reconstructed first-round book from the research data, not a scrape of today's website. Public portfolio pages over-report winners, and this graph has the same public-data bias. Investor edges are essentially Crunchbase through late 2015, plus Y Combinator.
Research book · 3-year follow-on
Canadian Medical Discoveries Fund vs Kairos
Not ranked
Whole-book follow-on hit rate 60.0% (3 of 5 labeled deals). 95% Wilson interval 23.1%–88.2%. Vintage-weighted base rate 42.9%. This is not a fund return.
Not ranked. A book needs at least 15 labeled deals with a vintage base rate. This one has 5.
Vs same-vintage base rate
+17.1 pp
60.0% on 5 deals vs 42.9%
Vs median VC book
+9.7 pp
60.0% on 5 deals vs 50.3%
Vs top-quartile VC
-6.5 pp
60.0% on 5 deals vs 66.5%
Vs Y Combinator
-10.6 pp
50.0% on 4 deals vs 60.6%
Ranked when at least 15 labeled deals have a vintage base rate. Rank is the average-rank percentile of shrunk excess (20 pseudo-deals at that book's vintage base rate) among eligible VC books that clear the same minimum. 100 is best. The whole book is never compared to Kairos's top-50 hit rate.
What Kairos would have said
Scores are the model’s percentile at each company’s first observed funding event, not at a later round. That matches this fund’s entry only when the fund was in the first-round syndicate. A deal is flagged when its percentile clears that vintage’s top-50 cutoff. The whole book is not compared to the top-50 hit rate.
Deals with a score
5
Mean model percentile
55
Flagged deals
11/1 followed on
Five-year exit, secondary
Five-year exit labels are observable mainly for 2005–2010. A missing later exit is not counted as a failure. This panel is not the ranking.
Hit rate 40.0% (2 of 5). 95% Wilson interval 11.8%–76.9%.
Vs exit base rate
+26.6 pp
40.0% on 5 deals vs 13.4%
Vs median VC exit book
—
No overlapping vintages
Vs top-quartile exit book
—
No overlapping vintages
Companies
5 labeled follow-on deals, 0 matched without an observable label (dropped, not counted as failures).
| Company | Vintage | Follow-on | Kairos percentile | Flagged |
|---|---|---|---|---|
| Inimex Pharmaceuticalsinimexpharma.com | 2004 | Yes | 95 | Yes |
| Agrisoma Biosciencesagrisoma.com | 2009 | No | 87 | — |
| Viron Therapeuticsvironinc.com | 2006 | No | 50 | — |
| Gemin X Pharmaceuticalsgeminx.com | 2008 | Yes | 23 | — |
| Protiva Biotherapeuticsprotivabio.com | 2006 | Yes | 20 | — |